|
|
| Formerly known as: |
| IDEC Pharmaceuticals Corp |
 |
| Primary Symbols & Exchanges: |
| BIIB - NASDAQ |
|
|
| Primary Industry: |
| Biotechnology |
|
|
SIC Industry Code:
|
|
NAICS Industry Code:
|
|
Thomson Financial Business Description:
| The Group's principal activity is the research, development, manufacture and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. The Group's two commercial products, Rituxan (r) (rituximab) and Zevalin (r) (ibritumomab tiuxetan) are for use in the treatment of certain B-cell non-Hodgkin's lymphomas (B-cell NHLs). Rituxan is a genetically engineered, chimeric murine/human monoclonal antibody designed to harness the patient's own immune mechanisms to destroy normal and malignant B cells. Zevalin, the Group's radioimmunotherapy product approved for treatment of certain B-cell NHL, delivers targeted immunotherapy by means of injectable radiation to target sites expressing the CD20 antigen, such as lymphatic B-cell tumors. The Group acquired Syntonix Pharmaceuticals Inc in Jan 2007. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on Biogen Idec Inc
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
